{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T09:00:17Z","timestamp":1791450017070,"version":"4.3.3"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2007,3,30]],"date-time":"2007-03-30T00:00:00Z","timestamp":1175212800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0\/"},{"start":{"date-parts":[[2007,3,30]],"date-time":"2007-03-30T00:00:00Z","timestamp":1175212800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      The amplicon on 8p11.2 is reported to be found in up to 10% of breast carcinomas. It has been demonstrated recently that this amplicon has four separate cores. The second core encompasses important oncogene candidates, including the fibroblast growth factor receptor 1 (\n                      <jats:italic>FGFR1<\/jats:italic>\n                      ) gene. Recent studies have demonstrated that specific\n                      <jats:italic>FGFR1<\/jats:italic>\n                      amplification correlates with gene expression and that FGFR1 activity is required for the survival of a\n                      <jats:italic>FGFR1<\/jats:italic>\n                      amplified breast cancer cell line.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      <jats:italic>FGFR1<\/jats:italic>\n                      amplification was analysed in tissue microarrays comprising a cohort of 880 unselected breast tumours by means of chromogenic\n                      <jats:italic>in situ<\/jats:italic>\n                      hybridisation using inhouse-generated\n                      <jats:italic>FGFR1<\/jats:italic>\n                      -specific probes. Chromogenic\n                      <jats:italic>in situ<\/jats:italic>\n                      hybridisation signals were counted in a minimum 30 morphologically unequivocal neoplastic cells. Amplification was defined as &gt;5 signals per nucleus in more than 50% of cancer cells or when large gene copy clusters were seen.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      <jats:italic>FGFR1<\/jats:italic>\n                      amplification was observed in 8.7% of the tumours and was significantly more prevalent in patients &gt;50 years of age and in tumours that lacked HER2 expression. No association was found with other histological parameters. Survival analysis revealed\n                      <jats:italic>FGFR1<\/jats:italic>\n                      amplification as an independent prognostic factor for overall survival in the whole cohort. Subgroup analysis demonstrated that the independent prognostic impact of\n                      <jats:italic>FGFR1<\/jats:italic>\n                      amplification was only seen in patients with oestrogen-receptor-positive tumours, where\n                      <jats:italic>FGFR1<\/jats:italic>\n                      amplification was the strongest independent predictor of poor outcome.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      Given that up to 8.7% of all breast cancers harbour\n                      <jats:italic>FGFR1<\/jats:italic>\n                      amplification and that this amplification is an independent predictor of overall survival, further studies analysing the\n                      <jats:italic>FGFR1<\/jats:italic>\n                      as a potential therapeutic target for breast cancer patients are warranted.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/bcr1665","type":"journal-article","created":{"date-parts":[[2007,4,30]],"date-time":"2007-04-30T11:51:33Z","timestamp":1177933893000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":232,"title":["FGFR1 amplification in breast carcinomas: a chromogenic in situhybridisation analysis"],"prefix":"10.1186","volume":"9","author":[{"given":"Somaia","family":"Elbauomy Elsheikh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew R","family":"Green","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryou BK","family":"Lambros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas C","family":"Turner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew J","family":"Grainge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Des","family":"Powe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian O","family":"Ellis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge S","family":"Reis-Filho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2007,3,30]]},"reference":[{"key":"1630_CR1","first-page":"4360","volume":"57","author":"F Courjal","year":"1997","unstructured":"Courjal F, Cuny M, Simony-Lafontaine J, Louason G, Speiser P, Zeillinger R, Rodriguez C, Theillet C: Mapping of DNA amplifications at 15 chromosomal localizations in 1875 breast tumors: definition of phenotypic groups. Cancer Res. 1997, 57: 4360-4367.","journal-title":"Cancer Res"},{"key":"1630_CR2","first-page":"1077","volume":"60","author":"M Cuny","year":"2000","unstructured":"Cuny M, Kramar A, Courjal F, Johannsdottir V, Iacopetta B, Fontaine H, Grenier J, Culine S, Theillet C: Relating genotype and phenotype in breast cancer: an analysis of the prognostic significance of amplification at eight different genes or loci and of p53 mutations. Cancer Res. 2000, 60: 1077-1083.","journal-title":"Cancer Res"},{"key":"1630_CR3","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1158\/1541-7786.MCR-05-0128","volume":"3","author":"V Gelsi-Boyer","year":"2005","unstructured":"Gelsi-Boyer V, Orsetti B, Cervera N, Finetti P, Sircoulomb F, Rouge C, Lasorsa L, Letessier A, Ginestier C, Monville F, et al: Comprehensive profiling of 8p11-12 amplification in breast cancer. Mol Cancer Res. 2005, 3: 655-667. 10.1158\/1541-7786.MCR-05-0128.","journal-title":"Mol Cancer Res"},{"key":"1630_CR4","doi-asserted-by":"publisher","first-page":"7281","DOI":"10.1038\/sj.onc.1208892","volume":"24","author":"LM Prentice","year":"2005","unstructured":"Prentice LM, Shadeo A, Lestou VS, Miller MA, deLeeuw RJ, Makretsov N, Turbin D, Brown LA, Macpherson N, Yorida E, et al: NRG1 gene rearrangements in clinical breast cancer: identification of an adjacent novel amplicon associated with poor prognosis. Oncogene. 2005, 24: 7281-7289. 10.1038\/sj.onc.1208892.","journal-title":"Oncogene"},{"key":"1630_CR5","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1002\/gcc.2870070407","volume":"7","author":"C Theillet","year":"1993","unstructured":"Theillet C, Adelaide J, Louason G, Bonnet-Dorion F, Jacquemier J, Adnane J, Longy M, Katsaros D, Sismondi P, Gaudray P, et al: FGFRI and PLAT genes and DNA amplification at 8p12 in breast and ovarian cancers. Genes Chromosomes Cancer. 1993, 7: 219-226. 10.1002\/gcc.2870070407.","journal-title":"Genes Chromosomes Cancer"},{"key":"1630_CR6","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1038\/sj.onc.1202739","volume":"18","author":"F Ugolini","year":"1999","unstructured":"Ugolini F, Adelaide J, Charafe-Jauffret E, Nguyen C, Jacquemier J, Jordan B, Birnbaum D, Pebusque MJ: Differential expression assay of chromosome arm 8p genes identifies frizzled-related (FRP1\/FRZB) and fibroblast growth factor receptor 1 (FGFR1) as candidate breast cancer genes. Oncogene. 1999, 18: 1903-1910. 10.1038\/sj.onc.1202739.","journal-title":"Oncogene"},{"key":"1630_CR7","doi-asserted-by":"publisher","first-page":"5235","DOI":"10.1038\/sj.onc.1208741","volume":"24","author":"MJ Garcia","year":"2005","unstructured":"Garcia MJ, Pole JC, Chin SF, Teschendorff A, Naderi A, Ozdag H, Vias M, Kranjac T, Subkhankulova T, Paish C, et al: A 1 Mb minimal amplicon at 8p11-12 in breast cancer identifies new candidate oncogenes. Oncogene. 2005, 24: 5235-5245. 10.1038\/sj.onc.1208741.","journal-title":"Oncogene"},{"key":"1630_CR8","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1158\/0008-5472.CAN-03-1022","volume":"64","author":"ME Ray","year":"2004","unstructured":"Ray ME, Yang ZQ, Albertson D, Kleer CG, Washburn JG, Macoska JA, Ethier SP: Genomic and expression analysis of the 8p11-12 amplicon in human breast cancer cell lines. Cancer Res. 2004, 64: 40-47. 10.1158\/0008-5472.CAN-03-1022.","journal-title":"Cancer Res"},{"key":"1630_CR9","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.cancergencyto.2004.03.013","volume":"155","author":"ZQ Yang","year":"2004","unstructured":"Yang ZQ, Albertson D, Ethier SP: Genomic organization of the 8p11-p12 amplicon in three breast cancer cell lines. Cancer Genet Cytogenet. 2004, 155: 57-62. 10.1016\/j.cancergencyto.2004.03.013.","journal-title":"Cancer Genet Cytogenet"},{"key":"1630_CR10","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.cytogfr.2005.01.001","volume":"16","author":"VP Eswarakumar","year":"2005","unstructured":"Eswarakumar VP, Lax I, Schlessinger J: Cellular signaling by fibroblast growth factor receptors. Cytokine Growth Factor Rev. 2005, 16: 139-149. 10.1016\/j.cytogfr.2005.01.001.","journal-title":"Cytokine Growth Factor Rev"},{"key":"1630_CR11","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1083\/jcb.200107119","volume":"157","author":"BE Welm","year":"2002","unstructured":"Welm BE, Freeman KW, Chen M, Contreras A, Spencer DM, Rosen JM: Inducible dimerization of FGFR1: development of a mouse model to analyze progressive transformation of the mammary gland. J Cell Biol. 2002, 157: 703-714. 10.1083\/jcb.200107119.","journal-title":"J Cell Biol"},{"key":"1630_CR12","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1083\/jcb.200505098","volume":"171","author":"W Xian","year":"2005","unstructured":"Xian W, Schwertfeger KL, Vargo-Gogola T, Rosen JM: Pleiotropic effects of FGFR1 on cell proliferation, survival, and migration in a 3D mammary epithelial cell model. J Cell Biol. 2005, 171: 663-673. 10.1083\/jcb.200505098.","journal-title":"J Cell Biol"},{"key":"1630_CR13","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/S1535-6108(02)00150-2","volume":"2","author":"K Suyama","year":"2002","unstructured":"Suyama K, Shapiro I, Guttman M, Hazan RB: A signaling pathway leading to metastasis is controlled by N-cadherin and the FGF receptor. Cancer Cell. 2002, 2: 301-314. 10.1016\/S1535-6108(02)00150-2.","journal-title":"Cancer Cell"},{"key":"1630_CR14","doi-asserted-by":"publisher","first-page":"6652","DOI":"10.1158\/1078-0432.CCR-06-1164","volume":"12","author":"JS Reis-Filho","year":"2006","unstructured":"Reis-Filho JS, Simpson PT, Turner NC, Lambros MB, Jones C, Mackay A, Grigoriadis A, Sarrio D, Savage K, Dexter T, et al: FGFR1 emerges as a potential therapeutic target for lobular breast carcinomas. Clin Cancer Res. 2006, 12: 6652-6662. 10.1158\/1078-0432.CCR-06-1164.","journal-title":"Clin Cancer Res"},{"key":"1630_CR15","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1186\/1471-2407-6-245","volume":"6","author":"A Letessier","year":"2006","unstructured":"Letessier A, Sircoulomb F, Ginestier C, Cervera N, Monville F, Gelsi-Boyer V, Esterni B, Geneix J, Finetti P, Zemmour C, et al: Frequency, prognostic impact, and subtype association of 8p12, 8q24, 11q13, 12p13, 17q12, and 20q13 amplifications in breast cancers. BMC Cancer. 2006, 6: 245-10.1186\/1471-2407-6-245.","journal-title":"BMC Cancer"},{"key":"1630_CR16","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1002\/path.2004","volume":"209","author":"JS Reis-Filho","year":"2006","unstructured":"Reis-Filho JS, Pinheiro C, Lambros MB, Milanezi F, Carvalho S, Savage K, Simpson PT, Jones C, Swift S, Mackay A, et al: EGFR amplification and lack of activating mutations in metaplastic breast carcinomas. J Pathol. 2006, 209: 445-453. 10.1002\/path.2004.","journal-title":"J Pathol"},{"key":"1630_CR17","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1038\/modpathol.3800621","volume":"19","author":"JS Reis-Filho","year":"2006","unstructured":"Reis-Filho JS, Savage K, Lambros MB, James M, Steele D, Jones RL, Dowsett M: Cyclin D1 protein overexpression and CCND1 amplification in breast carcinomas: an immunohistochemical and chromogenic in situ hybridisation analysis. Mod Pathol. 2006, 19: 999-1009. 10.1038\/modpathol.3800621.","journal-title":"Mod Pathol"},{"key":"1630_CR18","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1038\/labinvest.3700390","volume":"86","author":"MB Lambros","year":"2006","unstructured":"Lambros MB, Simpson PT, Jones C, Natrajan R, Westbury C, Steele D, Savage K, Mackay A, Schmitt FC, Ashworth A, et al: Unlocking pathology archives for molecular genetic studies: a reliable method to generate probes for chromogenic and fluorescent in situ hybridization. Lab Invest. 2006, 86: 398-408. 10.1038\/labinvest.3700390.","journal-title":"Lab Invest"},{"key":"1630_CR19","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1016\/S0002-9440(10)64785-2","volume":"157","author":"M Tanner","year":"2000","unstructured":"Tanner M, Gancberg D, Di Leo A, Larsimont D, Rouas G, Piccart MJ, Isola J: Chromogenic in situ hybridization: a practical alternative for fluorescence in situ hybridization to detect HER-2\/neu oncogene amplification in archival breast cancer samples. Am J Pathol. 2000, 157: 1467-1472.","journal-title":"Am J Pathol"},{"key":"1630_CR20","first-page":"133","volume":"97","author":"J Isola","year":"2004","unstructured":"Isola J, Tanner M: Chromogenic in situ hybridization in tumor pathology. Methods Mol Med. 2004, 97: 133-144.","journal-title":"Methods Mol Med"},{"key":"1630_CR21","doi-asserted-by":"publisher","first-page":"4793","DOI":"10.1158\/1078-0432.CCR-0428-03","volume":"10","author":"J Isola","year":"2004","unstructured":"Isola J, Tanner M, Forsyth A, Cooke TG, Watters AD, Bartlett JM: Interlaboratory comparison of HER-2 oncogene amplification as detected by chromogenic and fluorescence in situ hybridization. Clin Cancer Res. 2004, 10: 4793-4798. 10.1158\/1078-0432.CCR-0428-03.","journal-title":"Clin Cancer Res"},{"key":"1630_CR22","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1002\/path.1357","volume":"200","author":"Z Madjd","year":"2003","unstructured":"Madjd Z, Pinder SE, Paish C, Ellis IO, Carmichael J, Durrant LG: Loss of CD59 expression in breast tumours correlates with poor survival. J Pathol. 2003, 200: 633-639. 10.1002\/path.1357.","journal-title":"J Pathol"},{"key":"1630_CR23","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1111\/j.1365-2559.1991.tb00229.x","volume":"19","author":"CW Elston","year":"1991","unstructured":"Elston CW, Ellis IO: Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology. 1991, 19: 403-410. 10.1111\/j.1365-2559.1991.tb00229.x.","journal-title":"Histopathology"},{"key":"1630_CR24","doi-asserted-by":"publisher","first-page":"37","DOI":"10.3322\/canjclin.56.1.37","volume":"56","author":"SE Singletary","year":"2006","unstructured":"Singletary SE, Connolly JL: Breast cancer staging: working with the sixth edition of the AJCC Cancer Staging Manual. CA Cancer J Clin. 2006, 56: 37-47.","journal-title":"CA Cancer J Clin"},{"key":"1630_CR25","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/BF01840834","volume":"22","author":"MH Galea","year":"1992","unstructured":"Galea MH, Blamey RW, Elston CE, Ellis IO: The Nottingham Prognostic Index in primary breast cancer. Breast Cancer Res Treat. 1992, 22: 207-219. 10.1007\/BF01840834.","journal-title":"Breast Cancer Res Treat"},{"key":"1630_CR26","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1002\/ijc.21004","volume":"116","author":"DM Abd El-Rehim","year":"2005","unstructured":"Abd El-Rehim DM, Ball G, Pinder SE, Rakha EA, Paish C, Robertson JFR, MacMillan D, Blamey RW, Ellis IO: High throughput protein expression analysis using tissue microarray technology of a large well characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses. Int J Cancer. 2005, 116: 340-350. 10.1002\/ijc.21004.","journal-title":"Int J Cancer"},{"key":"1630_CR27","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1002\/path.1559","volume":"203","author":"DM Abd El-Rehim","year":"2004","unstructured":"Abd El-Rehim DM, Pinder SE, Paish CE, Bell J, Blamey RW, Robertson JF, Nicholson RI, Ellis IO: Expression of luminal and basal cytokeratins in human breast carcinoma. J Pathol. 2004, 203: 661-671. 10.1002\/path.1559.","journal-title":"J Pathol"},{"key":"1630_CR28","doi-asserted-by":"publisher","first-page":"5367","DOI":"10.1158\/1078-0432.CCR-04-0220","volume":"10","author":"TO Nielsen","year":"2004","unstructured":"Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hu Z, Hernandez-Boussard T, Livasy C, Cowan D, Dressler L, et al: Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res. 2004, 10: 5367-5374. 10.1158\/1078-0432.CCR-04-0220.","journal-title":"Clin Cancer Res"},{"key":"1630_CR29","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1002\/(SICI)1098-2264(199808)22:4<268::AID-GCC2>3.0.CO;2-T","volume":"22","author":"S Bautista","year":"1998","unstructured":"Bautista S, Theillet C: CCND1 and FGFR1 coamplification results in the colocalization of 11q13 and 8p12 sequences in breast tumor nuclei. Genes Chromosomes Cancer. 1998, 22: 268-277. 10.1002\/(SICI)1098-2264(199808)22:4<268::AID-GCC2>3.0.CO;2-T.","journal-title":"Genes Chromosomes Cancer"},{"key":"1630_CR30","first-page":"523","volume":"54","author":"SW McLeskey","year":"1994","unstructured":"McLeskey SW, Ding IY, Lippman ME, Kern FG: MDA-MB-134 breast carcinoma cells overexpress fibroblast growth factor (FGF) receptors and are growth-inhibited by FGF ligands. Cancer Res. 1994, 54: 523-530.","journal-title":"Cancer Res"},{"key":"1630_CR31","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1002\/bdrc.10025","volume":"69","author":"X Coumoul","year":"2003","unstructured":"Coumoul X, Deng CX: Roles of FGF receptors in mammalian development and congenital diseases. Birth Defects Res C Embryo Today. 2003, 69: 286-304. 10.1002\/bdrc.10025.","journal-title":"Birth Defects Res C Embryo Today"},{"key":"1630_CR32","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/S1535-6108(04)00053-4","volume":"5","author":"S Roumiantsev","year":"2004","unstructured":"Roumiantsev S, Krause DS, Neumann CA, Dimitri CA, Asiedu F, Cross NC, Van Etten RA: Distinct stem cell myeloproliferative\/T lymphoma syndromes induced by ZNF198-FGFR1 and BCR-FGFR1 fusion genes from 8p11 translocations. Cancer Cell. 2004, 5: 287-298. 10.1016\/S1535-6108(04)00053-4.","journal-title":"Cancer Cell"},{"key":"1630_CR33","doi-asserted-by":"publisher","first-page":"14479","DOI":"10.1073\/pnas.0404438101","volume":"101","author":"J Chen","year":"2004","unstructured":"Chen J, Deangelo DJ, Kutok JL, Williams IR, Lee BH, Wadleigh M, Duclos N, Cohen S, Adelsperger J, Okabe R, et al: PKC412 inhibits the zinc finger 198-fibroblast growth factor receptor 1 fusion tyrosine kinase and is active in treatment of stem cell myeloproliferative disorder. Proc Natl Acad Sci USA. 2004, 101: 14479-14484. 10.1073\/pnas.0404438101.","journal-title":"Proc Natl Acad Sci USA"}],"container-title":["Breast Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/bcr1665.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/bcr1665\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/bcr1665.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T06:20:20Z","timestamp":1728368420000},"score":1,"resource":{"primary":{"URL":"https:\/\/breast-cancer-research.biomedcentral.com\/articles\/10.1186\/bcr1665"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,3,30]]},"references-count":33,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2007,12]]}},"alternative-id":["1630"],"URL":"https:\/\/doi.org\/10.1186\/bcr1665","relation":{},"ISSN":["1465-542X"],"issn-type":[{"value":"1465-542X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,3,30]]},"assertion":[{"value":"1 December 2006","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2007","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2007","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2007","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"R23"}}